Comparison Of The Efficacy And Safety Of Icotinib And Erlotinib In The Treatment Of Non-small Cell Lung Cancer: A Meta-analysis

Background:Lung cancer is the malignant tumor with the highest morbidity and mortality.Among them,about 80% are non-small cell lung cancer(NSCLC).Most of the patients have been found late,and platinum-based chemotherapy has been the preferred choice for treatment.However,due to its non-selective killing effect,it often causes major adverse reactions.New-epoch-oriented targeted epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)can better balance Efficacy and less,less adverse reactions.At present,the most commonly used EGFR-TKIs on the market in China are icotinib,erlotinib,and gefitinib.Objectives:This study was designed to compare the efficacy and safety of icotinib and erlotinib in the treatment of advanced non-small cell lung cancer(NSCLC)in order to provide reference for clinical drug selection.Methods:Pubmed,Web of science,medline,Wanfang,CKNI,and VIP were searched for references that were included in the study.The search time was from January 2010 to March 2018,and icotinib and erlotinib were collected for treatment.The relevant literature on the efficacy and safety of small cell lung cancer.After data extraction,meta-analysis was performed using Review Manage 5.3 statistical software.Outcome measures included objective effective rate(ORR=CR+PR)and disease control rate(DCR=CR+PR+ SD),adverse reactions,etc.The adverse reaction indicators included the incidence of total adverse reactions,the incidence of rash,the incidence of diarrhea,and the incidence of serious adverse reactions.The efficacy and safety of the two targeted drugs were compared.Results:A total of 8 articles were included.A total of 515 patients with advanced non-small cell lung cancer were enrolled,including 271 patients in the icotinib group and 244 patients in the erlotinib group.A meta-analysis comparing the effectiveness of the drugs showed that for ORR,the ethinib group was 1.53 times(95% CI: 1.04-2.25),p=0.03;compared with the erlotinib group,and there was no statistical difference in the DCR;Safety comparison,total adverse reaction rate,0.45 times(95% CI: 0.27-0.72)in erlotinib group,p=0.001,occurrence of rash,incidence of diarrhea,severe adverse reactions There was no statistical difference in rates.Conclusion:Icotinib and erlotinib have a better objective efficacy in the treatment of patients with non-small cell lung cancer,which means that there is more clinical remission,and there is no obvious difference in the rate of disease control.Differences;For the adverse reactions,the total adverse reactions of the icotinib group were relatively less.For the comparison of skin rashes,diarrhea,and serious adverse reactions,there was no significant difference between the two.The choice of drugs in the clinic was based on the specific conditions of the patients.